Equities Analysts Offer Predictions for MRKR FY2028 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Stock analysts at Brookline Capital Management decreased their FY2028 EPS estimates for shares of Marker Therapeutics in a research report issued to clients and investors on Thursday, May 15th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of $2.33 per share for the year, down from their previous forecast of $2.42. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. Brookline Capital Management also issued estimates for Marker Therapeutics’ FY2029 earnings at $8.45 EPS.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings results on Wednesday, May 21st. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.26. The firm had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.50 million. Marker Therapeutics had a negative net margin of 179.74% and a negative return on equity of 89.63%.

A number of other research firms have also weighed in on MRKR. WBB Securities reiterated a “strong-buy” rating and issued a $12.50 price objective on shares of Marker Therapeutics in a research note on Tuesday, April 1st. Canaccord Genuity Group initiated coverage on shares of Marker Therapeutics in a report on Wednesday, March 5th. They set a “buy” rating and a $8.00 price objective on the stock.

Marker Therapeutics Trading Down 1.8%

Shares of Marker Therapeutics stock opened at $1.11 on Monday. Marker Therapeutics has a 12-month low of $0.95 and a 12-month high of $5.99. The firm has a market capitalization of $12.56 million, a price-to-earnings ratio of -0.83 and a beta of 1.29. The firm’s 50 day simple moving average is $1.18 and its two-hundred day simple moving average is $2.21.

Institutional Investors Weigh In On Marker Therapeutics

Hedge funds have recently modified their holdings of the business. Millennium Management LLC acquired a new stake in shares of Marker Therapeutics in the fourth quarter valued at about $50,000. Northern Trust Corp increased its position in Marker Therapeutics by 66.9% during the fourth quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after purchasing an additional 21,703 shares during the last quarter. LPL Financial LLC acquired a new stake in Marker Therapeutics during the fourth quarter worth about $248,000. Aisling Capital Management LP increased its position in Marker Therapeutics by 3.5% during the fourth quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock worth $1,012,000 after purchasing an additional 11,084 shares during the last quarter. Finally, Blue Owl Capital Holdings LP acquired a new stake in Marker Therapeutics during the fourth quarter worth about $1,724,000. 22.39% of the stock is currently owned by institutional investors and hedge funds.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.